Thanks. I missed that early 2022 article on 3-71. It looks like it took that 21 months before it was peer reviewed published last week! (21 mos. is supposedly the average from top line to peer reviewed publication).
It's mentioning a planned trial for 2022 that never happened (also standard!), and the writer says, "The study will be a quasi-basket trial ...", and mentions in this context frontal lobe dementia (and I wonder if that possibly covers PDD ((Parkinson's Disease Dementia)) - as we have trialed that -, but with 2-73, I believe), as well as schizophrenia and AD.
Is "a quasi basket trial" one where 2 or 3 different diseases are tested against one drug? I hope so. I think that's a great way for us to go....if possible.
News 
Market Data 
Discover 
